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Phototherapies like photodynamic therapy (PDT), UVA1,
UVB, and PUVA treat skin diseases. These phototherapies
work because they alter cytokine profiles, change immune
cytotoxicity in the skin, and directly kill diseased cells by
apoptosis. Apoptosis is a term that only describes the
morphologic changes a cell undergoes during this mode
of cell death. The terms ‘‘immediate’’, ‘‘intermediate’’,
and ‘‘delayed’’ apoptosis segregate the different apoptotic
mechanisms into three kinetic categories, whereas the
terms preprogrammed cell death (pre-PCD) and pro-
grammed cell death (PCD) describe the underlying
mechanisms. Immediate apoptosis (T £ 0.5 h post-
exposure) is triggered by singlet-oxygen damage that
opens the mitochondrial megachannel, which can be
mediated by PDT or UVA1 radiation. It is a pre-PCD
mechanism of apoptosis, i.e., protein synthesis is not
required post-insult, because all the necessary compon-
Photons across the electromagnetic spectrum are used totreat various diseases. The longer wavelength photons areused to treat skin diseases because they penetrate to thedermal layer more efficiently than the shorter wave-lengths (Bruls et al, 1984). Visible light wavelengths (400–
700 nm) with one of several photosensitizers, i.e., photodynamic
therapy (PDT), are used to treat cancers (Schuitmaker et al, 1996;
Kato, 1998) and various skin diseases (Fritsch et al, 1998). The
longest ultraviolet (UV) wavelengths (UVA; 320–400 nm) with a
photosensitizer, such as 8-methoxypsoralen (PUVA), i.e., photochemo-
therapy, are used to treat psoriasis (Lauharanta, 1997; Gasparro et al,
1998) and cutaneous T cell lymphomas (Nestle et al, 1997). UVA1
wavelengths (340–400 nm) without any photosensitizer, i.e., UVA1
phototherapy, are used to treat various inflammatory skin diseases, such
as atopic dermatitis (Krutmann, 1996, 1997). UVA1 phototherapy is
also being investigated for the treatment of systemic lupus erythematosus
(McGrath, 1997) and cutaneous T cell lymphomas (Krutmann, personal
communication). The UVB wavelengths (290–320 nm), i.e., narrow-
band UVB (311 nm) phototherapy, are the shortest wavelengths used
to treat a variety of skin diseases (El-Ghorr and Norval, 1997). All these
phototherapies work because they alter cytokine profiles, modulate
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ents are constitutively synthesized and only need to be
activated. Intermediate apoptosis (T £ 4 h > 0.5 h) is
initiated by receptor cross-linking on the plasma
membrane, which can be achieved using high doses of
UVB or UVC radiation. It is also a pre-PCD mechanism.
Delayed apoptosis (T > 4 h) is induced by DNA damage
that can be caused by X-rays, PUVA, UVC, UVB, UVA,
and PDT. It is a PCD mechanism of apoptosis, i.e.,
protein synthesis is required post-insult. These three
apoptotic mechanisms each access one of two ‘‘points-
of-no-return’’ located on the mitochondrial membrane,
which activate different, but not mutually exclusive, final
pathways of apoptosis. This review discusses the latest
findings on these apoptotic mechanisms and their
implications in phototherapies. Key words: phototherapy/
radiation/reactive oxygen species/ultraviolet. Journal of
Investigative Dermatology Symposium Proceedings 4:17–23,
1999
immunologic cytotoxicity in the skin (Norris et al, 1997), and directly
kill diseased cells into apoptosis: the focus of this review.
WHAT IS APOPTOSIS?
Apoptosis is the ‘‘black hole’’ of cell death; it draws everything inward
and nothing escapes its’ biochemical event horizon.
It is one of two modes of cell death, necrosis is the other. The
apoptotic cells in UV-irradiated skin are called ‘‘sunburn cells’’ (Daniels
et al, 1961; F. Daniels Jr., see acknowledgment; Young, 1987). The
term ‘‘apoptosis’’ only refers to the morphologic changes (Kerr et al,
1972) that can be seen using light, fluorescent, or electron microscopy
(Fig 1). During apoptosis, the cell draws inward shrinking dramatically,
the plasma membrane ‘‘blebs’’, the endoplasmic reticulum forms
vacuoles, and the chromatin is digested and condenses along the nuclear
membrane, often forming spheres and/or crescent shapes. In the final
stages, the nucleus and the cell fragment form smaller compact units
called apoptotic bodies. These apoptotic cells and bodies are primarily
removed by nonprofessional phagocytes, e.g., keratinocytes in the skin;
however, if they are not readily removed by phagocytosis, they undergo
‘‘secondary necrosis’’. During secondary necrosis, the lysosomes rupture
and release hydrolytic enzymes into the cytoplasm causing further
destruction of internal components including the plasma membrane.
Once the plasma membrane loses integrity, the cell lyzes, releasing
hydrolytic enzymes into the extracellular space guaranteeing an
inflammatory response with possible tissue damage. The virtue of
apoptotic cell death is that it usually does not result in an inflammatory
response or tissue damage.
The term apoptosis was originally coined to describe only the
morphologic and ultrastructual changes that occurred during this mode
of cell death. However, this term did not include any biochemical
events or mechanistic differences, because at that time they were not
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Figure 1. An example of an apoptotic, or sunburn, cell showing some
characteristic morphologic changes associated with this mode of cell
death. Note the condensed chromatin along the nuclear membrane forming
sphere and crescent shapes and the dilated endoplasmic reticulum forming
vacuoles. The most prevalent characteristic of apoptosis is cell shrinkage. This
UVA1-irradiated Daudi B cell has about half the volume of its’ nonapoptotic
counterpart. Micrograph by D.P.Thomas.
known (Kerr et al, 1972). The biochemical events are now used to
characterize and quantitate apoptotic cells, and to classify the different
mechanisms. When cells undergo apoptosis, they dramatically shrink
in size, one of the many characteristics that can be used to quantitate
the percentages of these cells. This can be accomplished by counting
the cells using either various microscopic methods or flow cytometry
based on differences in their forward (size) versus side (granularity)
light-scattering profiles (Dive et al, 1992). Apoptotic cells also express
phosphatidylserine residues on the outer leaflet of their plasma mem-
branes, which can be tagged with labeled Annexin V. When combined
with dye exclusion (propidium iodide), the apoptotic cells can be
quantitated using either fluorescent microscopy or flow cytometry, for
unlike necrotic cells, they exclude vital dyes until their plasma
membranes lose integrity. During apoptosis, the mitochondrial trans-
membrane potential drops, either immediately (Kroemer et al, 1997;
Godar, 1999a) or sometime after 2 h (Bossy-Wetzel et al, 1998; Godar,
1999a), and can be measured using specific fluorescent dyes, such
as JC-1 (5,59,6,69-tetrachloro-1,19,3,39-tetraethylbenzimidazolcarbo-
cyanine iodide), along with flow cytometry (Salvioli et al, 1997) or
confocal microscopy. Activation of ‘‘initiator’’ caspases, like caspase 8,
can be monitored during some mechanisms of apoptosis, whereas
activation of some of the ‘‘executioner’’ caspases, like caspase 3, can
usually be detected (Thornberry and Lazebnik, 1998). Most of these
cysteine proteases can be specifically inhibited and/or assayed using
specific colorimetric- or fluorogenic-peptide substrates that contain
aspartate residues. The executioner caspases take charge of the destruct-
ive phase, or final frontier of apoptosis. Like a preplanned military
operation they strategically cut, modify, and destroy vital cellular
components, such as Bcl-2, retinoblastoma-associated protein (Rb),
nuclear lamina, U1 70-kDa small nuclear ribonuclear protein (involved
in RNA splicing), focal adhesion kinase, p21-activated kinase 2, protein
kinase C-γ, protein phosphatase 2A, poly(ADP-ribose) polymerase
(PARP), fodrin, gelsolin, and many others. Their activation and/or
destructive force can be documented with western blots. One of their
manoeuvres usually involves cleaving inhibitors of and/or possibly
directly activating both endogenous endonucleases that digest the
genomic DNA, a relatively late biochemical event. One endogenous
endonuclease only forms high molecular weight DNA fragments
(50–300 kilobase pairs) that can be resolved using pulsed-field gel
electrophoresis. The other endonuclease cleaves between nucleosomes
forming multiples of 200 bp units that can be observed as a characteristic
DNA ‘‘ladder’’ after agarose gel electrophoresis. Alternatively, the DNA
strand breaks can be tagged using terminal deoxynucleotidyl transferase-
mediated UTP nick end labeling (TUNEL), which is a good approach
for identifying the apoptotic cells in tissue sections. Recently, antibodies
to ε(γ–glutamyl)lysine, a proteolytic resistant product of transglutamin-
ase, can allow assessment of various therapies by monitoring the amount
of ε(γ– glutamyl)lysine present in patients’ blood, urine, or tissue-
sectioned biopsies. Caution is advised, however, because it is not yet
known if this product is formed during all apoptotic mechanisms.
These different approaches represent only a few ways to quantitate
apoptotic cells: the rest are beyond the scope of this review (see Cotter
and Martin, 1996).
WHY IS APOPTOSIS MEDICALLY IMPORTANT?
Apoptosis is receiving a lot of attention in the medical community
because it is involved in development, differentiation, maintenance of
homeostasis of the tissues and the immune system, and every altered
cellular state, or disease. An example of one important disease is cancer,
where cells continually divide and also ignore certain apoptotic death
signals and/or strategically evade immune surveillance. They can ignore
various death signals because specific genes required for the different
apoptotic mechanisms are mutated, such as p53 (Fisher, 1994), or
upregulated, such as Bcl-2 (Adams and Cory, 1998). Alternatively, they
can evade immune surveillance by expressing high levels of the Fas
ligand (FasL) on their membranes, thereby killing their approaching
immunologic opponents by engaging their Fas receptor (FasR) first
(Green and Ware, 1997). On the other hand, autoimmune diseases
can occur when either functional mutations in FasR/FasL or increased
levels of soluble FasL allow thymocytes to escape negative selection
(Nagata, 1998; Suzuki et al, 1998). To kill these cells requires a
therapeutic approach that will trigger an apoptotic mechanism that is
downstream of the FasR/FasL pathway. Thus, in order to assure
a favorable outcome when treating various diseases, a complete
understanding of the different apoptotic mechanisms is essential for
choosing the best therapeutic approach.
THE THREE KINETIC MECHANISMS OF APOPTOSIS:
IMMEDIATE, INTERMEDIATE, AND DELAYED.
PREPROGRAMMED AND PROGRAMMED CELL DEATHS
The terms ‘‘immediate’’, ‘‘intermediate’’, and ‘‘delayed’’ apoptosis
assemble the different pre-PCD and PCD mechanisms into three
kinetic categories (Fig 2). Immediate apoptosis is triggered in less than
half an hour and is a pre-PCD, or constitutive, mechanism, i.e., protein
synthesis is not required post-insult (Godar, 1996). Examples of some
insulting agents that trigger immediate pre-PCD apoptosis include
PDT, UVA1, and evidently any system that generates singlet-oxygen
damage to mitochondrial membranes (Ball et al, 1998; Kessel and Luo,
1998; Godar, 1999a). Intermediate apoptosis occurs to a significant
extent within 4 h (Wang et al, 1997), but requires more than half an
hour, and is a pre-PCD mechanism as well. Examples of some insulting
agents that initiate intermediate pre-PCD apoptosis include high doses
of either UVB (Martin et al, 1995; Aragane et al, 1998; Bossy-Wetzel
et al, 1998; Godar, 1999a, b) or UVC (200–290 nm; Rehemtulla et al,
1997) radiation, and any agent that activates a membrane receptor
containing a death domain, such as Fas/CD95/APO-1 (Ashkenazi and
Dixit, 1998; Godar, 1999b). Once cross-linked, these receptors usually
transduce a signal to the mitochondria through the proteolytic action
of caspases. Delayed apoptosis occurs well after 4 h (can take days) and
is a PCD, or inducible, mechanism, i.e., protein synthesis is required
post-insult (Godar, 1996). Examples of agents that induce primarily
delayed PCD apoptosis are UVB, UVC (Godar, 1996; Godar et al.,
1994), PUVA (Marks and Fox, 1991; Vowels et al, 1996; Yoo et al,
1996), X-rays (Olive and Durand, 1997; Godar, 1999a), and any agent
that causes significant DNA damage (Godar and Lucas, 1995; Kasibhatla
et al, 1998). DNA damage leads to the upregulation of certain gene
products, some of which are known to participate in apoptotic
cell death mechanisms; the death receptor ligand, FasRL, and the
mitochondrial pore-forming protein, Bax, and close relatives (e.g., Bid).
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Figure 2. The three kinetic categories of apoptosis and underlying
biochemical mechanisms: pre-PCD and PCD. Immediate apoptosis is
triggered within half an hour by UVA1, PDT, or any singlet oxygen generating
system. It is a pre-PCD mechanism of apoptosis, i.e., it does not require protein
synthesis post-insult. Immediate apoptosis is triggered by immediate (T , 0.5 h)
depolarization of the mitochondrial transmembrane potential. Intermediate
apoptosis occurs rapidly (T ø 4 h but . 0.5 h) and is initiated by high doses
of UVB or UVC radiation, cross-linking of certain death receptors, such as
FasR, and any superoxide anion generating system. It is also a pre-PCD
mechanism of apoptosis. The mitochondria are depolarized 2–4 h after exposure
by the action of caspases through receptor signaling. Moreover, high doses of
UVB and UVC also cause DNA damage and delayed apoptosis. Delayed
apoptosis is induced after 4 h by DNA damage that can be caused by PDT,
UVA, UVB, UVC, PUVA, or X-rays or any ROS-generating system. Delayed
apoptosis is a PCD mechanism, i.e., protein synthesis is required post-
insult. DNA damage either activates the transcription factor, AP-1, increasing
expression of the receptor Fas, or activates the transcription factor, p53,
increasing expression of the mitochondrial pore-forming protein Bax. In
addition, though it is not shown in the figure, UVA1 radiation gives a mixed
apoptotic mechanism that not only triggers immediate pre-PCD apoptosis, but
also induces delayed PCD apoptosis to some extent from DNA damage.
PHOTON-MEDIATED IMMEDIATE, INTERMEDIATE,
AND DELAYED APOPTOSIS: MITOCHONDRIA,
RECEPTORS, AND DNA
Immediate pre-PCD apoptosis can be triggered either by singlet-
oxygen or superoxide-anion damage to mitochondrial membranes
(Fig 3, left-hand side). Both UVA1 radiation and PDT primarily
mediate singlet-oxygen production triggering immediate pre-PCD
apoptosis by immediately depolarizing the mitochondrial transmem-
brane potential. Evidently, the megapore opens at the ‘‘S’’ site (sulfhydryl
sensitive) releasing apoptosis-inducing factor (AIF) unless cyclosporine
A (CsA) is present (Godar, 1999a). Immediate apoptosis can also be
triggered at the ‘‘P’’ site (pyrimidine nucleotide sensitive) by high levels
of superoxide anions (e.g. 1 mM vitamin K3); however, this mechanism
evidently involves release of cytochrome c (cyto c) because it is not
inhibited by CsA (Godar, unpublished observations). UVA1- (Pourzand
et al, 1997) and PDT- (He et al, 1996) triggered immediate pre-PCD
apoptosis can be ‘‘inhibited’’, i.e., stopped or slowed down, by
overexpression of Bcl-2, an antioxidant protein. Some of these Bcl-2
overexpressing cells survive and reproduce, as measured by clonogenic
platting; however, most of these cells still died a clonogenic death,
indicating that other cell death mechanisms are also activated, such as
intermediate and/or delayed apoptosis, and possibly necrosis as well.
Antioxidants, like glutathione (Godar, 1999a) and vitamin E (Godar
and Lucas, 1995), can inhibit UVA1-triggered immediate pre-PCD
apoptosis by scavenging most of the ROS before critical damage occurs
to the mitochondrial megapore. Antioxidants, however, only slow the
apoptotic process down because very few of the cells actually survived.
Thus, clonogenic survival data are important for determining if an
agent really stops apoptosis or simply delays the process. Regardless of
Figure 3. Model for all three kinetic mechanisms of apoptosis. The left
side of the figure shows two pathways for immediate pre-PCD apoptosis. The
far left-hand side of the figure shows what happens if singlet oxygen damage
causes the megapore to open at the ‘‘S’’ site, releasing AIF. Evidently another
immediate mechanism can be triggered when overwhelming amounts of
superoxide anions or other agents cause Bax/Bid to rapidly form a channel at
the ‘‘P’’ site. In this pathway, cyto c is released. The middle of the figure shows
two pathways for intermediate pre-PCD apoptosis initiated by high doses of
UVB or UVC radiation and any agent that causes cross-linking of a receptor
with a death domain, e.g., the Fas receptor (CD95/APO-1). It is known that
high doses of UVB or UVC radiation cause cross-linking of the Fas receptor
and recruitment of FADD, which in turn clusters procaspase 8 that becomes
an active protease. What is not known is whether or not Bax (or Bid), cyto c,
or postmitochondrial caspases, other than caspase 3, are involved in photon-
initiated intermediate apoptosis. This portion of the figure is somewhat
speculative but is based on knowledge from other systems. The other receptor
pathway involves caspase 8 directly cleaving procaspase 3 yielding active capsase
3 (Casp3) and apoptotic morphology. The far right side of the figure shows
two pathways for delayed PCD apoptosis induced by any agent that causes
DNA damage, such as PDT, UVA, UVB, UVC, PUVA, and X-rays. DNA
damage can activate the transcription factor, AP-1, increasing FasL expression
that engages FasR on the plasma membrane activating an intermediate pathway.
DNA damage can also activate the transcription factor, p53, increasing Bax
expression that directly activates an immediate pathway on the mitochondrial
membrane, bypassing the intermediate mechanisms altogether. Other pathways
may also be activated and many other gene products are known to be
upregulated; however, which genes belong to what delayed PCD apoptotic
mechanism and which genes belong to what survival mechanism remains to be
determined. Because transcription and translation are required for apoptosis to
proceed, these PCD mechanisms require some time to produce the products
that will either trigger (Bax) or initiate (Fas) the apoptotic morphology. In these
delayed apoptotic mechanisms, the mitochondrial transmembrane potential does
not depolarize for many hours (.4 h) and they cannot be inhibited with CsA.
These findings suggest that the ‘‘P’’ site of the megapore is ultimately involved
in DNA damage-induced PCD mechanisms and that the final pathway may
involve the pore-forming ability of Bax, or close relatives (e.g., Bid), and
subsequent release of cyto c.
the immediate mechanism that is triggered, i.e., ‘‘S’’ or ‘‘P’’ site, the
apoptotic morphology only begins to occur after either AIF or cyto c
is released from the mitochondria.
Intermediate pre-PCD apoptosis is usually initiated by receptor
cross-linking that can be achieved using high doses (.99.9% clonogenic
death) of UV radiation (Fig 3, middle to left). High-dose UVB- or
UVC-initiated intermediate apoptosis has a kinetic profile that matches
anti-Fas-initiated apoptosis (Martin et al, 1995; Rehemtulla et al, 1997;
Aragane et al, 1998; Bossy-Wetzel et al, 1998; Godar, 1999a). The
kinetics match because both mechanisms involve cross-linking of the
FasR (Rehemtulla et al, 1997; Aragane et al, 1998). Exactly how high
doses of UV cross-link the FasR is not yet known, but this process
may involve superoxide anions and/or hydroxyl radicals (Gorman et al,
1997). It is known, however, that FasL does not engage FasR because
apoptosis is not inhibited by a blocking antibody, such as ZB4.
Moreover, confocal microscopy, limiting immunoprecipitation, and
coimmunoprecipitation with FADD (Fas-associated death domain)
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Figure 4. Hypothetical model of the two ‘‘points-of-no-return’’ located
on the mitochondrial membrane. The figure shows the components of the
mitochondrial megachannel or megapore. Located on the outer mitochondrial
membrane of the megapore is the benzodiazepine receptor, protoporphyrin IX
(PpIX) is a ligand, and voltage dependent anion channel (VDAC) or porin,
along with Bcl-2 and/or Bcl-xL (antioxidant and inhibitory proteins), and Bax
and/or Bid (pore-forming proteins). Located on the inner mitochondrial
membrane is the adenine nucleotide transporter (ANT) and cyclophilin D,
which can bind cyclosporin A. In functioning cells, cytochrome c (cyto c) is
not released into the cytosol and apoptosis-inducing factor (AIF) is also
maintained inside the mitochondria. The ‘‘S’’ site evidently contains the
benzodiazepine receptor and ANT, while the ‘‘P’’ site contains VDAC and
cyclophilin D along with the translocated pore-forming protein, Bax, and its
inhibitory partner, Bcl-2. Although it is not currently known how Bcl-2 inhibits
both the ‘‘S’’ and ‘‘P’’ site mechanisms, it may do so through close proximity
to the benzodiazepine receptor where it could offer protection from ROS
damage while it could also inhibit pore formation by Bax. How cyto c is
released from the ‘‘P’’ site is not known (? in the figure), but it might exit
through a very large pore created by Bax and/or VDAC. Likewise, how AIF
is released from the ‘‘S’’ site is not known (? in the figure), but it might exit
through the benzodiazepine receptor and/or Bax. In addition, the exact
arrangement of the megapore components in three dimensions is not known
and other known components have been omitted from the figure. Thus, the
benzodiazepine receptor and VDAC may actually be next to each other with
Bcl-2 and Bax surrounding the exterior (i.e., fold the figure in half and look
from above). Furthermore, the arrangement of components is probably dynamic
rather than static, for under certain conditions Bax can translocate from the
outer to the inner member and cyclophilin D can translocate from the matrix
to the inner membrane at different sites.
confirmed that FasR was directly cross-linked by UV radiation. After
the FasR is cross-linked, FADD recruits procaspase 8 that becomes
active caspase 8, a premitochondrial initiator caspase. Caspase 8 can
either cleave Bid, which then forms a pore in the mitochondrial
membrane (Li et al, 1998), or it can by-pass the mitochondria by
directly cleaving procaspase 3 (Stennicke et al, 1998). Other receptors
with a death domain, like TNF, can also initiate intermediate apoptosis
(Ashkenazi and Dixit, 1998), and apparently play a role in some
photon-initiated apoptotic mechanisms (Schwarz et al, 1995; Sheikh
et al, 1998). In addition, another intermediate mechanism evidently
involves p53, which somehow causes translocation of preformed Fas
to the plasma membrane (Bennett et al, 1998). Although this mechanism
is not currently understood or reported for photon-mediated apoptosis,
it may be involved in the intermediate expression of surface FasL after
UVA1 irradiation of T cells (Morita et al, 1997). When these inter-
mediate mechanisms access a mitochondrial pathway, they only do so
at the ‘‘P’’ site because they cannot be inhibited by CsA.
Delayed PCD apoptosis is induced by DNA damage that can be
produced using visible light, UVA, UVB, UVC, or X-rays (Ley and
Applegate, 1985; Jones et al, 1987; Peak and Peak, 1991; Godar and
Lucas, 1995; Godar, 1999a). Besides mitochondrial membrane damage,
UVA radiation also causes DNA damage and some delayed apoptosis
(Godar and Lucas, 1995). Moreover, high doses of UV radiation not
only affect cellular targets on the plasma membrane and in the cytoplasm
(Schwarz, 1998), resulting in intermediate apoptosis, but also cause
DNA damage resulting in delayed apoptosis (Godar, 1999a). These
other affects confuse the interpretation of results and provide challenging
complications when designing experiments to understand the mechan-
isms of DNA-damage induced delayed apoptosis; however, in spite of
these challenging complications, two delayed PCD apoptotic mechan-
isms induced by DNA damage have emerged so far (Fig 3, right to left).
One DNA-damage-induced delayed apoptotic mechanism involves the
transcription factor AP-1, whereas the other involves the transcription
factor p53. In the first case, DNA damage leads to activation of the
transcription factor, AP-1. AP-1 binds to the FasL promoter increasing
FasL mRNA and subsequently FasL protein expression, which is
translocated to the plasma membrane (Kasibhatla et al, 1998). Note
that the opposite can occur in FasL-expressing cells (Giordano et al,
1997). This DNA damage-induced apoptotic mechanism is partly
understood for UVB radiation and some other DNA damaging agents,
such as etoposide and teniposide, which damage the DNA by inhibiting
topoisomerase II (Kasibhatla et al, 1998). A similar delayed apoptotic
mechanism may also occur with therapeutically relevant doses of UVA1
radiation both in vitro and in vivo, because delayed upregulation of FasL
expression and apoptosis have also been noted (Morita et al, 1997).
Moreover, DNA damage from X-rays has recently been reported to
result in delayed upregulation of FasL and subsequent apoptosis (Belka
et al, 1998). Upregulating Fas expression allows this delayed apoptotic
mechanism to initiate apoptosis by accessing an intermediate pre-PCD
pathway. The other DNA damage-induced apoptotic mechanism
involves the transcription factor, p53. Unlike UVA1 radiation, which
predominately induces a p53-independent mechanism, both UVB
(Wang et al, 1998) and UVC (Kimura et al, 1998) radiation primarily
induce a p53-dependent apoptotic mechanism (Godar, unpublished
results). Accumulation of p53 is linked to the delayed formation of
UVB-induced sunburn cell formation in skin, and mutations in p53
to the development of skin cancer (Zeigler et al, 1994; Brash et al,
1996). Moderate to high doses (,99.9% clonogenic death) of UVB
and UVC radiation cause accumulation of p53 and its alternatively
spliced form, p53as, which results in cell cycle arrest in G1 and G2,
respectively (Godar, unpublished results). Along with multitudes of
other gene products, UVB-induced p53 accumulation leads to increased
expression of Bax both in vitro and in vivo (Selvakumaran et al, 1994;
Reinke and Lozano, 1997; O’Grady et al, 1998). In addition, UVC
radiation also leads to increased expression of Bax (Kimura et al, 1998).
Bax can form a pore in the mitochondrial membrane that somehow
leads to the release of cyto c and subsequent apoptotic morphology.
PUVA also causes DNA damage (through psoralen cross-linking and
adduct formation), accumulation of p53, cell cycle arrest, and is a
delayed PCD mechanism of apoptosis (Marks and Fox, 1991; Johnson
et al, 1996; Vowels et al, 1996; Yoo et al, 1996; Godar, 1999a). Ionizing
radiation-induced DNA damage also causes accumulation of p53,
delayed PCD apoptosis (Clarke et al, 1993; Lowe et al, 1993), and
induction of Bax (Zhan et al, 1994). The p53-dependent delayed PCD
mechanism of apoptosis, unlike the AP-1-dependent mechanism,
bypasses the intermediate pathways altogether by directly accessing the
immediate pathway at the ‘‘P’’ site. Moreover, there appear to be other
delayed apoptotic mechanisms induced by DNA damage that do not
involve either p53 or AP-1; however, these other DNA damage-
induced delayed PCD apoptotic mechanisms are not very well under-
stood (Evan and Littlewood, 1998) and require future studies that are
carefully planned and executed to unravel these different pathways.
Each of the three apoptotic mechanisms have at least two alternate
pathways. These multiple, or ‘‘fail-safe’’, mechanisms and pathways
probably coexist to assure that the damaged cell does not survive to
reproduce genetic errors. All but one of these apoptotic pathways
either originate or culminate at one of two ‘‘points-of-no-return’’
located on the mitochondrial membrane.
THE TWO ‘‘POINTS-OF-NO-RETURN’’
Photon-mediated apoptotic mechanisms all access one of two ‘‘points-
of-no-return’’, beyond which the cell cannot be rescued from death.
One point-of-no-return, or commitment site, involves the opening of
the mitochondrial megapore (Kroemer et al, 1997) at the ‘‘S’’ site,
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whereas the other involves pore formation by either Bax (Jurgensmeier
et al, 1998) or Bid (Li et al, 1998) at the ‘‘P’’ site. The opening of the
megapore at either the ‘‘S’’ or the ‘‘P’’ commitment sites is controlled
by dithiol oxidation and pyrimidine nucleotide status, respectively
(Costantini et al, 1996). The sulfhydryl-sensitive ‘‘S’’ site is inhibited
by CsA or increased levels of reduced thiols, like glutathione (Marchetti
et al., 1997), whereas the pyrimidine nucleotide-sensitive ‘‘P’’ site is
not inhibited by CsA but is inhibited by increased levels of reduced
pyrimidine nucleotides, like NADH.
The mitochondrial megapore is comprised of a large complex of
proteins that spans the outer and inner membranes (Fig 4). The
proteins located on the outer membrane of the megapore include the
benzodiazepine receptor (protoporphyrin IX, PpIX, is a ligand) and
the voltage-dependent anion channel (VDAC). The proteins located
on the inner membrane of the megachannel include the adenine
nucleotide transporter and cyclophilin D. In addition, other proteins
are associated with the cytoplasmic face of the megapore, like hexo-
kinase (not shown in the figure), or purify along with the megapore,
such as Bcl-2, Bax, Bag-1, and F1-ATPase (Marzo et al, 1998).
When the large megapore opens at the ‘‘S’’ site, the mitochondrial
transmembrane potential immediately drops and apoptosis-inducing
factor (AIF), is released unless CsA or bongkrekic acid are present
(Kroemer et al, 1997; Susin et al., 1999). Singlet oxygen-generating
systems, such as UVA1 or PDT, can immediately depolarize the
mitochondrial transmembrane potential (∆Ψm) and evidently open the
megapore at the ‘‘S’’ site, because these systems can be inhibited by
CsA or reduced glutathione (Godar, 1999a). The other point-of-no-
return involves a pore created by either Bax or Bid at the ‘‘P’’ site,
which somehow leads to translocation of cyto c from the mitochondria
to the cytosol (Jurgensmeier et al, 1998; Li et al, 1998). All but one
signaling pathway initiates the release of cyto c (Kluck et al, 1997;
Green and Reed, 1998), and evidently so can superoxide-anion
generating systems, like menadione (vitamin K3; Godar, 1999a). High
levels of superoxide anions produced from vitamin K3 (e.g., 1 mM)
can also trigger immediate apoptosis (,15 min), but this immediate
mechanism occurs at the ‘‘P’’ site as well, because it cannot be
inhibited by CsA (Godar, unpublished results). Excessive production
of superoxide anions by pyruvate with UVA1 radiation evidently also
affects the ‘‘P’’ site, because CsA has no affect on that immediate
apoptotic mechanism. Ethanol, like reduced glutathione, reduces this
impressive effect (Godar, 1999a), because the activity of alcohol
dehydrogenase increases the reduced pyrimidine nucleotide pool,
which regulates the ‘‘P’’ site. The mitochondrial megapore ‘‘S’’ and
‘‘P’’ sites can both be inhibited by Bcl-2 or Bcl-XL (Susin et al, 1996;
Kluck et al, 1997; Marzo et al, 1998); however, once either AIF is
released from the ‘‘S’’ site, or cyto c is released from the ‘‘P’’ site, one
or the other final pathway of apoptosis begins, and the cells fate is sealed.
THE TWO FINAL APOPTOTIC PATHWAYS
Although not much is known about the final pathways of photon-
induced apoptosis, other systems give clues as to what these mechanisms
may involve. The two points-of-no-return and corresponding final
pathways of apoptosis can be distinguished either by the time displace-
ment of mitochondrial transmembrane depolarization and/or by
shielding the megapores ‘‘S’’ site using a blocker, like CsA (Godar,
1999a). Both UVA1 radiation and PDT generate singlet oxygen,
which immediately depolarize mitochondrial membranes and causes
immediate apoptosis unless inhibited by CsA. Though not conclusively
proven for singlet oxygen-triggered immediate apoptosis, megapore
opening has been shown to release AIF unless either CsA or bongkrekic
acid are present (Marchetti et al, 1996). CsA can distinguish between
the two final apoptotic pathways by binding to cyclophilin D and
shielding the release of AIF (Kroemer et al, 1997). Once AIF is released,
it cleaves procaspase 3 to form active caspase 3 that triggers rapid
apoptotic morphology (Susin et al, 1996; Kroemer et al, 1997; Marzo
et al, 1998). UVA1 radiation is similar to this mechanism because it
also activates a caspase 3-like activity (Godar, unpublished results).
Unlike the ‘‘S’’ site, all but one signal transduction pathway utilizes
the ‘‘P’’ site where the mitochondrial transmembrane potential takes
3 h or more to depolarize (Bossy-Wetzel et al, 1998; Godar, 1999a).
Bax or Bid form a pore at the ‘‘P’’ site, which somehow allows cyto
c to translocate to the cytosol where it associates with Apaf-1 (and
dATP or ATP) recruiting procaspase 9 to become active caspase 9.
This postmitochondrial initiator caspase then activates an executioner
caspase cascade involving caspase 3 and eventually leads to mitochondrial
transmembrane depolarization, perhaps by cleaving Bcl-2 (Cheng et al,
1997). Contrasting the ‘‘S’’ site mechanism, the ‘‘P’’ site mechanism is
not inhibited by CsA because it does not prevent the release of cyto
c if Bax or Bid form a pore. Thus, the two points-of-no-return and
their corresponding final apoptotic pathways can be distinguished by
monitoring the mitochondrial transmembrane potential over time in
the absence or presence of CsA (Godar, 1999a).
SUMMARY
In light of these recent findings, one might ask what practical application
knowledge about the different apoptotic mechanisms might have in
the therapeutic setting. Different therapies take advantage of initiating
different apoptotic mechanisms and knowledge of how these mechan-
isms work will enable clinicians to choose the best therapeutic approach
when treating different diseases and patients. Several factors, such as
the dose and wavelength of radiation, the concentration and type of
photosensitizer (if any), the drugs taken by or dietary habits of a
patient, and the redox potential and pyrimidine nucleotide status of
the cells along with genetic mutations, are all important for determining
which apoptotic mechanism will ultimately prevail.
These points are illustrated in the following scenarios. First, low to
moderate doses (,99.9% reproductive death) of the shorter UV
wavelengths (UVB/C) initiate delayed apoptosis via DNA damage,
while high doses (.99.9% reproductive death) initiate the intermediate
mechanism via receptor cross-linking, which short-circuits the delayed
apoptotic mechanism. Unlike the shorter wavelengths (UVB/C), even
very high therapeutic doses of the longer UV wavelengths (UVA)
triggers immediate apoptosis via mitochondrial damage, which short-
circuits both the intermediate and delayed mechanisms. Second, high
concentrations and/or certain types of photosensitizing agents can go
beyond the mitochondrial damage that causes immediate apoptosis and
result in necrosis. Third, drugs or dietary habits that inhibit or promote
an apoptotic mechanism can influence the effectiveness of a therapy.
For example, CsA is used on transplant patients and it inhibits immediate
apoptosis triggered by either PDT or UVA1-mediated singlet-oxygen
production by interfering with AIF release from the ‘‘S’’ site. Because
X-rays, PUVA, or narrow-band UVB phototherapies cause DNA
damage that induces delayed apoptosis through the ‘‘P’’ site of the
megapore, these therapies would not be affected by CsA. Similarly,
antioxidant vitamins (especially vitamin E) and dietary habits that
increase antioxidant levels interfere with PDT- or UVA1-triggered
immediate apoptosis by scavenging singlet oxygen before it causes the
megapore to open at the ‘‘S’’ site. Besides using alternate phototherapies
like UVB, PUVA, or X-rays, these dietary habits could be reduced
and/or eliminated during the course of PDT or UVA1 phototherapies.
In addition, some phototherapies might benefit if a vehicle other than
ethanol were chosen for skin applications of photosensitizers, drugs,
or other agents. On the other hand, promoters of the different apoptotic
mechanisms may improve some phototherapeutic approaches, such as
vitamin K3 or pyruvate with UVA1 phototherapy. Finally, some diseased
cells have mutations in critical genes required for a particular apoptotic
mechanism and consequently do not die. For example, lupus auto-
immune cells do not undergo negative selection in the thymus due to
mutations in the FasR/FasL pathway. UVA1 phototherapy, unlike
UVB or PUVA, which aggravate lupus, may help these patients by
triggering immediate apoptosis of autoimmune cells at the mitochon-
drial level, downstream of the defective FasR/FasL pathway. Further-
more, using only one therapeutic approach at a time to treat certain
diseases, like cancer, will select for mutant populations resistant to
undergoing that particular apoptotic mechanism, which will lead to
eventual failure of that approach. Altering or combining therapeutic
approaches that induce p53-dependent (e.g., PUVA, UVB, and X-ray)
with those that trigger p53-independent (e.g., UVA1 and PDT)
22 GODAR JID SYMPOSIUM PROCEEDINGS
apoptotic mechanisms may prevent selection for p53 mutants or
overexpressors of Bcl-2, respectively. Future clinical research will
determine which phototherapeutic approaches are most effective for
each patient and disease.
The author recognizes that Dr. Farrington Daniels Jr. was the first to characterize and
coin the term ‘‘sunburn cells’’. This paper is dedicated to him on his 80th birthday (born
on September 29, 1918). The author is grateful to Drs Francis P. Gasparro and Anne
D. Lucas for excellent critical reviews of this manuscript. The author also thanks Drs
Douglas R. Green and Nigel J. Waterhouse for helpful scientific discussions. In addition,
apologies are extended to those many investigators whose important contributions could
not be described in detail or cited at all due to space limitations.
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